- Case report
- Open Access
Port site metastasis following diagnostic laparoscopy for a malignant Gastro-intestinal stromal tumour
© Davies et al; licensee BioMed Central Ltd. 2008
- Received: 13 February 2008
- Accepted: 24 May 2008
- Published: 24 May 2008
Gastro-Intestinal stromal tumours (GISTs) are rare and our understanding of their natural history and optimal treatment are continually evolving. Port site metastasis after laparoscopy for a GIST is an extremely rare phenomenon.
We report a case with relevant imaging and discuss factors that may have contributed to the development of this isolated metastasis.
Percutaneous methods of sampling GIST tumours for analysis should be avoided if at all possible. When necessary, prophylactic measures should be utilised to minimise the risk of seeding.
- Stromal Tumour
- Prophylactic Measure
- Port Site Metastasis
Gastro-Intestinal stromal tumors (GISTs) are rare, and our understanding of their natural history and optimal treatment are continually evolving. This case report of a port site metastasis following laparoscopy for a malignant GIST is, to our knowledge, only the second documented case. As well as an outline of the case itself, the question as to why these arise and what the optimal treatment should be is also discussed.
A 75 year old female presents to her General Practitioner with symptoms of lethargy, weight loss and occasional vomiting. Abdominal examination reveals a large mass in the epigastrium and blood investigations reveal a microcytic anaemia with a Haemoglobin of 9.4 g/dL. Her only past medical history includes atrial fibrillation and a total abdominal hysterectomy and bilateral salpingo-oophorectomy for benign disease.
At diagnostic laparoscopy (performed to obtain tissue diagnosis and assess potential tumour stage), the large mass anterior to the stomach was biopsied as were the peritoneal seedlings. Histology demonstrated a malignant GIST, strongly positive for CD117. She was discussed at the regional Upper GI Multi-Disciplinary meeting, and the decision made to commence systemic oncological therapy with Glivec (Imatinib).
In light of the confirmation of a port site metastasis (PSM), she is due to be discussed again in the MDT meeting prior to making a final decision regarding further treatment. The evidence base for the treatment of port site recurrences originating from common tumours is limited. In the context of this particular case i.e. a GI Stromal tumour, it is non-existent.
Gastro-intestinal stromal tumours are the most common mesenchymal tumour affecting the GI tract. They may present in a variety of ways, can range from small to very large and demonstrate a great diversity in their malignant potential. Tumours are often positive for the c-KIT (CD117) protein which is a tyrosine kinase receptor and is the most sensitive and specific marker. Mutations of this CD117 proto-oncogene are associated with stromal tumours and hence the use of long term Imatinib (a CD117 inhibitor) in their treatment .
In many ways, the presentation in this case with a malignant GIST is fairly typical. Bleeding, and resultant anaemia, is often the precipitating event leading up to presentation. Malignant tumours often have a palpable mass at diagnosis and response to Glivec (although somewhat variable) can be dramatic.
Generally speaking, pre-operative biopsy is not advised in patients who are radiologically diagnosed with a GIST and resectable. However, in the event of more widespread disease, where histological confirmation is required to commence oncological treatment, endoscopic biopsy techniques are preferred in order to limit the possibility of peritoneal contamination. Failing this, percutaneous techniques (either radiologically guided or via laparoscopy) remain the only alternative, both presenting a theoretical risk of tumour seeding [2, 3].
Port Site metastases (PSM) although rare, have been extensively documented for other gynaecological and GI malignancies. When they occur, they often do so in the presence of advanced disease, and it is not uncommon for them to occur in isolation [4, 5]. Their presence is usually associated with poor long term outcomes.
Mechanisms thought to be involved in the development of PSMs include high pressure CO2 insufflation, the degree of tumour manipulation during surgery, direct seeding during unprotected tumour/instrument withdrawal as well as the biological characteristics of the cancer itself [6, 7].
In this particular case, laparoscopy (and hence gas insufflation) was required because of failure of alternative techniques to establish the diagnosis. The tumour was biopsied and the biopsy instrument removed through the port (in theory protecting the specimen from contacting the layers of the abdominal wall), although the port itself then required removal. The advanced nature of the tumour also increased the risk of a PSM but as far as we know, the port did not enter the peritoneal cavity at the site of an existing peritoneal metastasis.
As far as the authors are aware, there is only one previously documented case of port site metastasis (PSM) following laparoscopy for a stromal tumour . Although an extremely rare phenomenon, the implication is that prophylactic measures of preventing seeding should be undertaken when performing laparoscopy for stromal tumours. Such measures could include the use of protective retrieval bags or peritoneal lavage with anti-adhesive or cytocidal solutions, although evidence for the latter is limited to say the least. Where possible, the use of any percutaneous technique to obtain diagnosis should be avoided.
In this particular case, further treatment options could include surgical resection of the port site or the use of a second line agent such as sunitinib. This latter decision would be made on the assumption that the development of a port site metastasis whilst on first line treatment, confers the development of tumour resistance to this intial therapy. This is a phenomenon that has been increasingly well documented in the literature , and successfully treated with further medical therapy.
Percutaneous methods of obtaining histological evidence of GIST tumours, should be avoided if at all possible. When necessary, the reporting of PSM's suggests that prophylactic measures should be utilised to minimise the risk of seeding.
Written consent was obtained from the patient for publication of this case report
- Rubin BP, Prof Heinrich MC, Prof Corless CL: Gastrointestinal stromal tumour. Lancet. 2007, 369 (9574): 1731-1741. 10.1016/S0140-6736(07)60780-6.View ArticlePubMedGoogle Scholar
- Blackstein ME, Blay JY, Corless C: Gastro-intestinal stromal tumours : consensus statement on diagnosis and treatment. Can J Gastroenterol. 2006, 20: 157-163.PubMed CentralPubMedGoogle Scholar
- Von Mehren M, Watson JC: Gastrointestinal stromal tumours. Hematol Oncol Clin North Am. 2005, 19: 547-564. 10.1016/j.hoc.2005.03.010.View ArticlePubMedGoogle Scholar
- Wang PH, Yuan CC, Lin G, Ng HT, Chao HT: Risk factors contributing to early occurrence of port site metastases of laparoscopic surgery for malignancy. Gynecol Oncol. 1999, 72 (1): 38-44. 10.1006/gyno.1998.5128.View ArticlePubMedGoogle Scholar
- Shoup M, Brennan MF, Karpeh MS, Gillern SM, McMahon RL, Conlon KC: Port site metastasis after diagnostic laparoscopy for upper gastrointestinal tract malignancies: an uncommon entity. Ann Surg Oncol. 2002, 9 (7): 632-636.View ArticlePubMedGoogle Scholar
- Martinez J, Targarona EM, Balagué C, Pera M, Trias M: Port site metastasis. An unresolved problem in laparoscopic surgery. Int Surg. 1995, 80 (4): 315-321.PubMedGoogle Scholar
- Schaeff B, Paolucci V, Thomopoulos J: Port site recurrences after laparoscopic surgery. A review. Dig Surg. 1998, 15 (2): 124-134. 10.1159/000018605.View ArticlePubMedGoogle Scholar
- Kaczmarek D, Blanc P, Balique JG, Porcheron J: Port-site metastasis after laparoscopic resction of a duodenal stromal tumor. Ann Chir. 2001, 126 (7): 677-679. 10.1016/S0003-3944(01)00576-4.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.